Corbus Pharmaceuticals Holdings, Inc. (CRBP) — AI Analysis & Mentions

Corbus reported a wider net loss, but still sits on $138.2M in cash after R&D spending for its pipeline. Despite analysts cutting the 12-month price target (now $41.11), this still implies a 272% upside. The consensus is 'Buy,' but investors must weigh near-term losses against potential long-term gains in the biotech pipeline.